Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

F0250000

Fluorouracil

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

5-Fluorouracil, 2,4-Dihydroxy-5-fluoropyrimidine, 5-FU, 5-Fluoro-2,4(1H,3H)-pyrimidinedione

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C4H3FN2O2
Número de CAS:
51-21-8
Peso molecular:
130.08
Beilstein:
127172
Número MDL:
MFCD00006018
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329799645
NACRES:
NA.24
En este momento no podemos mostrarle ni los precios ni la disponibilidad

grado

pharmaceutical primary standard

familia API

fluorouracil

fabricante / nombre comercial

EDQM

mp

282-286 °C (dec.) (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

FC1=CNC(=O)NC1=O

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

Clave InChI

GHASVSINZRGABV-UHFFFAOYSA-N

Información sobre el gen

human ... TYMS(7298)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Fluorouracil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000762

Fluorouracil impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000763

Fluorouracil impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000791

Fluorouracil impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0000765

Fluorouracil impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000764

Fluorouracil impurity C, European Pharmacopoeia (EP) Reference Standard

1279000

Fluorouracil, United States Pharmacopeia (USP) Reference Standard

1279054

Fluorouracil Related Compound E, United States Pharmacopeia (USP) Reference Standard

1279065

Fluorouracil Related Compound F, United States Pharmacopeia (USP) Reference Standard

1279019

Fluorouracil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1279021

Fluorouracil Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

Fluorouracil Related Compound A, certified reference material, pharmaceutical secondary standard

PHR2866

Fluorouracil Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2867

Fluorouracil Related Compound E, certified reference material, pharmaceutical secondary standard

PHR2868

Fluorouracil Related Compound F, certified reference material, pharmaceutical secondary standard

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palabra de señalización

Danger

Frases de peligro

H301,H351

Clasificaciones de peligro

Acute Tox. 3 Oral - Carc. 2

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 4

1 of 4

5-Fluorouracil for synthesis

Sigma-Aldrich

8.18505

5-Fluorouracil

5-Fluorouracil Potent antitumor agent.

Sigma-Aldrich

343922

5-Fluorouracil

Oxaliplatin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1528

Oxaliplatin

7-Ethyl-10-hydroxycamptothecin ≥98% (HPLC), powder

Sigma-Aldrich

H0165

7-Ethyl-10-hydroxycamptothecin

André Bp van Kuilenburg et al.
Pharmacogenomics, 14(7), 799-811 (2013-05-09)
5-fluorouracil (5-FU) remains the cornerstone of all currently applied regimens for the treatment of patients with cancers of the gastrointestinal tract, breast, and head and neck. Unfortunately, a large variation in the clearance of 5-FU has been observed between patients
Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
Guido Deboever et al.
Clinical colorectal cancer, 12(1), 8-14 (2012-10-30)
Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because
John M L Ebos et al.
EMBO molecular medicine, 6(12), 1561-1576 (2014-11-02)
Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and
Taroh Satoh et al.
The oncologist, 19(7), 712-719 (2014-06-22)
The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico